Galapagos NV: Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...
IGA: Good Diversification And Fully-Covered Distribution (Rating Upgrade)
Voya Global Advantage and Premium Opportunity Fund has a 10.74% yield, diversification benefits, and well-covered ...
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...
F3 Encounters Encouraging Geology in Final Drillholes of 2024 Program
F3 Uranium Corp (TSXV: FUU) (OTCQB: FUUFF) ("F3" or "the Company") is pleased to announce that persistent prospective ...